Nanoparticle chemo and DNA-Repair blocker join forces against tough cancers
NCT ID NCT02769962
First seen Jun 30, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This trial investigates a combination of two drugs: EP0057, a chemotherapy drug wrapped in a nanoparticle to help it reach cancer cells, and olaparib, which stops cancer cells from fixing DNA damage. The study includes adults with small cell lung cancer, bladder cancer, or prostate cancer that has come back or stopped responding to standard treatments. The goal is to find the safest dose and see whether the combination can shrink tumors or slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EP0057 (nanoparticle camptothecin) and olaparib
- What this could lead to
- If successful, this combination could offer a new treatment option for people with hard-to-treat small cell lung, bladder, or prostate cancers.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits are uncertain. The drugs may cause serious side effects like low blood counts or fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new pill outsmart resistant prostate cancer?
- A second look: MRI screening may spot hidden prostate cancers